<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>MONTELUKAST</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, p. 161</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>MONTELUKAST</b></p>

<p><b>RxNorm: 88249</b></p>

<p><b>ATC: R03DC03 </b></p></td>
<td valign="top"><p><b>ANTICONVULSANT ENZYMATIC INDUCERS</b></p>

<p><b>CLASS CODE: N03A-001</b></p></td>
<td valign="top"><p>Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped<b>. </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>MONTELUKAST</b></p>

<p><b>RxNorm: 88249</b></p>

<p><b>ATC: R03DC03 </b></p></td>
<td valign="top"><p><b>RIFAMPICIN</b></p>

<p><b>RxNorm: 9384 </b></p>

<p><b>ATC: J04AB02</b></p></td>
<td valign="top"><p>Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped<b>.</b></p></td>
</tr>

</tbody>
</table>

